Charles River Laboratories International, Inc. (CRL)

NYSE: CRL · Services-Commercial Physical & Biological Research · Wilmington, MA · filing with the SEC since 1999

Full chart Alerts Compare

Grade5.2

◀ Past 6.0● Present 5.1▶ Future 4.1

Overview Business Financials Grade Forecast Sentiment Ownership People Filings Patents Chart

The companyfiscal 2025, as filed

Revenue$4.02B-0.9%

Net income-$142M-662.1%

Earnings per share$-2.91-1555.0%

Operating cash flow$738M+0.4%

Cash$214M+9.8%

Debt$2.14B-4.6%

Shareholders’ equity$3.17B-8.6%

Shares, diluted49.6M-4.0%

Return on equity-4.5%

The recordfrom its filings

Filings in 2026103

Newest filingNov 10 · SCHEDULE 13G/A

Annual reportFeb 18, 2026

Quarterly reportNov 4, 2026

Next report due10-K by Feb 25

Insider sales, 12 months$52.1M

Insider buys, 12 months$0.00

Patents granted62

Filer categoryLarge accelerated filer

Trailing twelve months to Sep 2026Revenue $3.98BNet income $42.6MCash from operations $622Mthe four newest filed quarters added

Left: the newest annual report, with the change on the year before. Right: counted from the company's own filings with the SEC.

Revenue and net income by fiscal yearRevenueNet income

16171819202122232425

As filed, in USD. Nothing here is a forecast.

News

Nov 10, 2026 · SEC EDGAR · Form SCHEDULE 13G/A

Large holder update, amended

Open the filing on sec.gov

Nov 9, 2026 · SEC EDGAR · Form 4

Insider trade report

Open the filing on sec.gov

Nov 9, 2026 · SEC EDGAR · Form 8-K

Current report

Open the filing on sec.gov

Nov 5, 2026 · SEC EDGAR · Form SCHEDULE 13G/A

Large holder update, amended

Open the filing on sec.gov

Nov 4, 2026 · SEC EDGAR · Form 10-Q

Quarterly report

Open the filing on sec.gov

Nov 4, 2026 · SEC EDGAR · Form 8-K

Results released

Open the filing on sec.gov

Oct 26, 2026 · SEC EDGAR · Form 4

Insider trade report

Open the filing on sec.gov

Oct 23, 2026 · SEC EDGAR · Form 4

Insider trade report

Open the filing on sec.gov

Oct 22, 2026 · SEC EDGAR · Form 144

Notice of intended sale

Open the filing on sec.gov

Oct 21, 2026 · SEC EDGAR · Form 144

Notice of intended sale

Open the filing on sec.gov

An outside story is shown by its headline, its source and its link only. The SI reads the page when you ask it to break one down.

SI brieffrom the record

Core business

Charles River Laboratories International, Inc. is classed by the SEC under Services-Commercial Physical & Biological Research (industry code 8731), based in Wilmington, MA. Discovery and Safety Assessment was 60% of fiscal 2025 revenue.

Newest on the record

Large holder update, amended on Nov 10. Before it, insider trade report on Nov 9.

What is due next

The 10-K for the period to Dec 27, 2026, due by Feb 25, 2027.

About CRL

Charles River Laboratories International, Inc. is classed by the SEC under Services-Commercial Physical & Biological Research (industry code 8731), based in Wilmington, MA. In its latest annual figures on file, for the fiscal year ended 2025-12-27, it reported revenue of $4.0 billion and a loss of $142 million (its filed statements).

IndustryServices-Commercial Physical & Biological Research

HeadquartersWilmington, MA

Business modelProject business

ExchangeNYSE

Filing since1999

Fiscal year endsDec 27

SEC number (CIK)1100682

Peers on fileINCY, ICLR, MEDP, IQV

Who runs it

Financial performance

In fiscal 2025 Charles River Laboratories International’s revenue was $4.02 billion, down 0.9% from $4.05 billion the year before. It made a net loss of $142.2 million.

Annual report, filed Feb 18, 2026.

Financial statements

The grade

Charles River Laboratories International grades 5.2 of 10 against its own industry, the 12 companies in Services-Commercial Physical & Biological Research. All nine metrics are read as filed.

◀ Past6.0

● Present5.1

▶ Future4.1

How the grade is made

Forecast

Every forecast is registered before the outcome, with the rule that settles it. A miss stays on the page.

Company forecasts

SI Assistanton CRL · research, not advice